Cytosorbents (CTSO) investor relations material

Executive summary

• Q3 operating cash flow was positive $43,000 excluding $251,000 of restructuring payments, meeting the second-half breakeven objective; total quarterly cash burn including restructuring was ~$200,000.

• Priorities: sustain breakeven, restore profitable core growth, pursue U.S. authorization for DrugSorb-ATR, and realize HemoDefend-BGA’s strategic value.

Financial highlights

• Q3 revenue was $9.7M, up 3% YoY and 1% sequentially; gross profit rose 10% to $7.3M as cost of goods sold fell 15% to $2.4M.

• Q3 operating expenses fell 11% to $8.5M, or 13% excluding $250,000 of restructuring charges; operating loss improved 59% to $1.2M.

• Q3 net loss improved 42% to $1.8M, or $0.58/share; adjusted net loss was $1.5M, or $0.48/share, and adjusted EBITDA loss narrowed 86% to $284,000.

• 9M revenue was $28.2M vs. $27.8M; gross margin rose to 73% from 71%, operating expenses fell 9% to $27.4M, and operating loss improved 34% to $6.9M.

• 9M adjusted EBITDA loss improved 45% to $4.0M; GAAP net loss was $11.4M vs. $2.7M, reflecting a non-cash FX swing from a $9.1M gain to a $1.9M loss.

Outlook and guidance

• Targeting product gross margins consistently in the mid-70% range; Q3 product gross margin was 75%, up from 69% in Q1.

• Focus is to sustain operating cash flow at or near breakeven while selectively investing in sales growth; quarterly cash flow may vary with orders, collections, and working capital.

• A new DrugSorb-ATR De Novo submission for ticagrelor removal is planned for early 2027, subject to study completion and regulatory interactions; a separate DOAC submission is expected in 2027.

• FDA’s statutory review period is 150 days; Breakthrough Device designation and priority review may expedite the process, but timing and outcome remain uncertain.